Physician profile
Misty Mcdowell
NPI 1790834265
$5,319.42
in general payments reported to CMS, 2019-2025
17 companies · $36.29 in 2025
The $36.29 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $428 · 2022: $775 · 2023: $2,705 · 2024: $1,376 · 2025: $36.29.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,059 · Education: $57.63.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,059.28 |
| Education | $57.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $935.09 | 2022-2024 | Invega Sustenna, Spravato, Invega Trinza |
| Abbvie INC. | $855.30 | 2021-2025 | |
| Alkermes, INC. | $682.11 | 2022-2024 | Aristada, Lybalvi, Vivitrol |
| Axsome Therapeutics, INC. | $631.61 | 2022-2024 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $549.17 | 2021-2024 | Austedo Xr, Austedo, Uzedy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $462.56 | 2022-2024 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $307.21 | 2021-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Sunovion Pharmaceuticals INC. | $207.17 | 2021 | |
| Lundbeck LLC | $197.65 | 2021-2024 | Rexulti, Abilify Maintena |
| Vanda Pharmaceuticals INC. | $141.19 | 2022-2024 | Fanapt, Hetlioz |
| Almatica Pharma LLC | $125.00 | 2024 | Loreev Xr, Teriparatide |
| Supernus Pharmaceuticals, INC. | $83.36 | 2023-2024 | Qelbree, Qelbree |
| Neurocrine Biosciences, INC. | $58.12 | 2023-2024 | Ingrezza |
| Corium, LLC | $35.80 | 2024 | Azstarys |
| E.R. Squibb & Sons, L.L.C. | $18.12 | 2024 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $15.49 | 2024 | Trintellix |
| Sage Therapeutics, LLC | $14.47 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Misty Mcdowell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.